Isorhamnetin alleviates symptoms and inhibits oxidative stress levels in rats with pulmonary arterial hypertension

Document Type : Original Article

Authors

1 School of Clinical Medicine, Ningxia Medical University,Yinchuan, China

2 General Hospital of Ningxia Medical University, Yinchuan, China

3 Department of Foreign Language Teaching, Ningxia Medical University, Yinchuan, China

4 School of Public Health and Management, Ningxia Medical University, Yinchuan, China

5 People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China

6 Department of Pharmacology, College of Pharmacy, Ningxia Medical University, Yinchuan, China

7 Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University, Yinchuan, China

8 NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China

9 Ningxia Characteristic Traditional Chinese Medicine Modernization Engineering Technology Research Center, Ningxia Medical University, Yinchuan, China

Abstract

Objective(s): Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular disease with high mortality. Isorhamnetin (ISO), one of the main natural flavonoids extracted from sea buckthorn, has pharmacological effects such as anti-inflammatory, anti-proliferative and antioxidant. This study aimed to investigate the protective effect of ISO on PAH and its relationship with the phosphorylation of the c-Src tyrosine kinase (p-c-src)/NOX1 signaling pathway.
Materials and Methods: Ninety-five rats were randomly divided into five groups. The normal group received only a subcutaneous injection of saline, while the other groups received a subcutaneous injection of monocrotaline(MCT) (60 mg/kg) to establish a PAH model. The treatment group received ISO (50, 100, 150 mg/kg/d) treatment for 21 days, and after 21 days, all rat lung tissues were separated.
Results: The results showed that ISO could significantly improve the hemodynamics of MCT-induced PAH rats, such as mean pulmonary artery pressure (mPAP) and right ventricular systolic pressure (RVSP), and had inhibitory effects on right ventricular hypertrophy in PAH rats, and on pulmonary vascular remodeling in PAH rats. In addition, ISO can reduce the content of 5-hydroxytryptamine (5-HT) in PAH rats, increase the expression of Nrf2 protein in the lung tissue of PAH rats, activate the antioxidant system, enhance the activity of SOD in lung tissue of PAH rats, and inhibit NOX1, 5-HTT, p-c-src and Proliferating Cell Nuclear Antigen(PCNA) protein expression, and decrease MDA content.
Conclusion: Our research confirmed the therapeutic effect of ISO on MCT-induced PAH rats, which may be related to regulating the p-c-src/NOX1 signaling pathway.

Keywords

Main Subjects

References

1. Hu P, Xu Y, Jiang Y, Huang J, Liu Y, Wang D, et al. The mechanism of the imbalance between proliferation and ferroptosis in pulmonary artery smooth muscle cells based on the activation of SLC7A11. Eur J Pharmacol 2022; 928: 175093.
2. Yu M, Wu X, Wang J, He M, Han H, Hu S, et al. Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways. Int J Med Sci 2022; 19: 681-694.
3. Poyatos P, Gratacós M, Samuel K, Orriols R, Tura-Ceide O. Oxidative stress and antioxidant therapy in pulmonary hypertension. Antioxidants (Basel) 2023; 12: 1006-1022.
4. Türck P, Salvador I, Campos-Carraro C, Ortiz V, Bahr A, Andrades M, et al. Blueberry extract improves redox balance and functional parameters in the right ventricle from rats with pulmonary arterial hypertension. Eur J Nutr 2022; 61: 373-386.
5. Earley S, Leblanc N. Serotonin receptors take the TRiPV4 highway in chronic hypoxic pulmonary hypertension. Focus on “TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension”. Am J Physiol Cell Physiol 2013; 305: C690-692.
6. Dai Z, Liu Y, Hsu J, Yeh J, Chen I, Wu J, et al. The xanthine derivative KMUP-1 attenuates serotonin-induced vasoconstriction and K⁺-channel inhibitory activity via the PKC pathway in pulmonary arteries. Int J Biol Sci 2015; 11: 633-642.
7. Hood K, Mair K, Harvey A, Montezano A, Touyz R, MacLean M. Serotonin signaling through the 5-HT receptor and NADPH oxidase 1 in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2017; 37: 1361-1370.
8. Gong G, Guan Y, Zhang Z, Rahman K, Wang S, Zhou S, et al. Isorhamnetin: A review of pharmacological effects. Biomed Pharmacother 2020; 128: 110301- 110316.
9. Stochmal A, Rolnik A, Skalski B, Zuchowski J, Olas B. Antiplatelet and anticoagulant activity of isorhamnetin and its derivatives isolated from sea buckthorn berries, measured in whole blood. Molecules 2022; 27: 4429-4442.
10. Zhao T, Yang T, Gong L, Wu P. Isorhamnetin protects against hypoxia/reoxygenation-induced injure by attenuating apoptosis and oxidative stress in H9c2 cardiomyocytes. Gene 2018; 666: 92-99.
11. Jamali-Raeufy N, Baluchnejadmojarad T, Roghani M, Keimasi S, Goudarzi M. Isorhamnetin exerts neuroprotective effects in STZ-induced diabetic rats via attenuation of oxidative stress, inflammation and apoptosis. J Chem Neuroanat 2019; 102: 101709.
12. Yang B, Ma L, Wei Y, Cui Y, Li X, Wei Y, et al. Isorhamnetin alleviates lipopolysaccharide-induced acute lung injury by inhibiting mTOR signaling pathway. Immunopharmacol immunotoxicol 2022; 44: 387-399.
13. Chang Z, Wang J, Jing Z, Ma P, Xu Q, Na J, et al. Protective effects of isorhamnetin on pulmonary arterial hypertension: In vivo and in vitro studies. Phytother Res 2020; 34:2730-2744.
14. Leopold J, Maron B. Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension. Int J Mol Sci 2016; 17: 761-774.
15. Ryan J, Archer S. The right ventricle in pulmonary arterial hypertension: Disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 2014; 115: 176-188.
16. Chen T, Chen J, Chen C, Zheng H, Chen Y, Liu M, et al. Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension. Pediatr pulmonol 2021; 56: 2250-2258.
17. Chetan C, Suryawanshi P, Patnaik S, Soni N, Rath C, Pareek P, et al. Oral versus intravenous sildenafil for pulmonary hypertension in neonates: A randomized trial. BMC pediatr 2022; 22: 311-317.
18. Mandras S, Kovacs G, Olschewski H, Broderick M, Nelsen A, Shen E, et al. Combination therapy in pulmonary arterial hypertension-targeting the nitric oxide and prostacyclin pathways. J Cardiovasc Pharmacol Ther 2021; 26: 453-462.
19. Shi Y, Shu H, Wang X, Zhao H, Lu C, Lu A, et al. Potential advantages of bioactive compounds extracted from traditional chinese medicine to inhibit bone destructions in rheumatoid arthritis. Front Pharmacol 2020; 11: 561962-561977.
20. Sun L, Ye X, Wang L, Yu J, Wu Y, Wang M, et al. A review of traditional chinese medicine, buyang huanwu decoction for the treatment of cerebral small vessel disease. Front Neurosci 2022;16:942188-942199.
21. Wang Y, Gao X, Chen X, Li Q, Li X, Zhao J. Seabuckthorn reverses high-fat-diet-induced obesity and enhances fat browning via activation of AMPK/SIRT1 pathway. Nutrients 2022; 14: 2903-2915.
22. Skalski B, Lis B, Pecio Ł, Kontek B, Olas B, Żuchowski J, et al. Isorhamnetin and its new derivatives isolated from sea buckthorn berries prevent HO/Fe-Induced oxidative stress and changes in hemostasis. Food Chem Toxicol 2019; 125: 614-620.
23. Xu Y, Tang C, Tan S, Duan J, Tian H, Yang Y. Cardioprotective effect of isorhamnetin against myocardial ischemia reperfusion (I/R) injury in isolated rat heart through attenuation of apoptosis. J Cell Mol Med 2020; 24: 6253-6262.
24. Afnan, Saleem A, Akhtar M, Sharif A, Akhtar B, Siddique R, et al. Anticancer, cardio-protective and anti-inflammatory potential of natural-sources-derived phenolic acids. Molecules 2022; 27: 7286-7306.
25. Tang C, Luo Y, Li S, Huang B, Xu S, Li L. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats. Biomed Pharmacother 2021; 133: 111081-111089.
26. Li H, Liu Q, Yue Y, Wang S, Huang S, Huang L, et al. Celastrol attenuates the remodeling of pulmonary vascular and right ventricular in monocrotaline-induced pulmonary arterial hypertension in rats. Cardiovasc Diagn Ther 2022; 12: 88-102.
27. Mikhael M, Makar C, Wissa A, Le T, Eghbali M, Umar S. Oxidative stress and its implications in the right ventricular remodeling secondary to pulmonary hypertension. Front Physiol 2019; 10: 1233-1242.
28. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol 2018; 217: 1915-1928.
29. Panahi Kokhdan E, Ahmadi K, Sadeghi H, Sadeghi H, Dadgary F, Danaei N, et al. Hepatoprotective effect of stachys pilifera ethanol extract in carbon tetrachloride-induce hepatotoxicity in rats. Pharm Biol 2017; 55: 1389-1393.
30. Lu H, Xiao H, Dai M, Xue Y, Zhao R. Britanin relieves ferroptosis-mediated myocardial ischaemia/reperfusion damage by upregulating GPX4 through activation of AMPK/GSK3β/Nrf2 signalling. Pharm Biol 2022; 60: 38-45.
31. Tungalag T, Park K, Yang D. Butein ameliorates oxidative stress in H9c2 cardiomyoblasts through activation of the NRF2 signaling pathway. Antioxidants (Basel) 2022; 11: 1430-1442.
32. Dai Z, Zhu M, Peng Y, Jin H, Machireddy N, Qian Z, et al. Endothelial and smooth muscle cell interaction via FoxM1 signaling mediates vascular remodeling and pulmonary hypertension. Am  J Respir Crit Care Med 2018; 198: 788-802.
33. Jing X, Jiang T, Dai L, Wang X, Jia L, Wang H, et al. Hypoxia-induced autophagy activation through NF-κB pathway regulates cell proliferation and migration to induce pulmonary vascular remodeling. Exp Cell Res 2018; 368: 174-183.
34. Bellí G, Colomina N, Castells-Roca L, Lorite N. Post-translational modifications of PCNA: Guiding for the best DNA damage tolerance choice. J Fungi (Basel) 2022; 8: 621-649.
35. Gradisch R, Szöllősi D, Niello M, Lazzarin E, Sitte H, Stockner T. Occlusion of the human serotonin transporter is mediated by serotonin-induced conformational changes in the bundle domain. J Biol Chem 2022; 298: 101613-101626.
36. Tangmahakul N, Makoom P, Surachetpong S. Assessment of platelet and plasma serotonin in canine pulmonary hypertension secondary to degenerative mitral valve disease. Front Vet Sci 2021;8:695492-695500.
37. Wang H, Chen W, Shen J, Ye T, Xie H. Fbxw7 attenuating glucose metabolism by promotes taxol sensitivity of colon cancer cells through downregulating oxidase 1 (Nox1). Ann Transl Med 2021; 9: 886-896.
38. Wong W, Knowles J, Morse J. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: Implication for a role in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2005; 33: 438-446.
Iranian Journal of Basic Medical Sciences
Volume 27, Issue 12
December 2024
Pages 1616-1623

Files

Share

How to cite

Statistics